SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017462
Filing Date
2023-05-04
Accepted
2023-05-04 07:16:18
Documents
70
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kymr-20230331.htm   iXBRL 10-Q 2882535
2 EX-31.1 kymr-ex31_1.htm EX-31 21530
3 EX-31.2 kymr-ex31_2.htm EX-31 21321
4 EX-32.1 kymr-ex32_1.htm EX-32 12257
5 EX-32.2 kymr-ex32_2.htm EX-32 12047
  Complete submission text file 0000950170-23-017462.txt   10454005

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kymr-20230331_cal.xml EX-101.CAL 57496
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kymr-20230331_pre.xml EX-101.PRE 387070
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kymr-20230331_def.xml EX-101.DEF 244700
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kymr-20230331.xsd EX-101.SCH 69656
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kymr-20230331_lab.xml EX-101.LAB 556934
64 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20230331_htm.xml XML 2072279
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 23886443
SIC: 2836 Biological Products, (No Diagnostic Substances)